Fig. 2.

Intra-ACC infusion or systemic administration of 3-MPA has no significant effects on 3-CSRT performance. 3-MPAwas administered i.p. at doses of0, 1, 3, or 10mg/kg (a–d; n=7, 7, 7, and 6, respectively), or locally within the ACC at 0, 1, 10, 100, or 1 M concentrations (e–h; n=9, 7, 6, 3, and 5, respectively). Performance was measured in terms of percent accuracy (a, e), percent omissions (b, f), premature responses (c, g), and total responses (d, h). Data are presented as mean±SEM. Asterisks indicate significant differences from vehicle (*p<0.05; **p<0.01)